COVID-19 Patients Putting on the Brakes with PAR1 Autoantibodies

• References

• 1 Violi F, Harenberg J, Pignatelli P, Cammisotto V. COVID-19 and long-COVID thrombosis: from clinical and basic science to therapeutics. Thromb Haemost 2024; 124 (04) 286-296
• 2 Greistorfer T, Jud P. Pathophysiological aspects of COVID-19-associated vasculopathic diseases. Thromb Haemost 2023; 123 (10) 931-944
• 3 Han X, Nieman MT. The domino effect triggered by the tethered ligand of the protease activated receptors. Thromb Res 2020; 196: 87-98
• 4 Garishah FM, Huskens D, Pramudo SG. et al. Hyperresponsive platelets and a reduced platelet granule release capacity are associated with severity and mortality in COVID-19 patients. Thromb Haemost 2022; 122 (12) 2001-2010
• 5 Reinshagen L, Nageswaran V, Heidecke H. et al. Protease-activated receptor-1 IgG autoantibodies in patients with COVID-19. Thromb Haemost 2023; (e-pub ahead of print).
• 6 von Brühl M-L, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
• 7 Rolling CC, Sowa MA, Wang TT. et al. P2Y12 inhibition suppresses proinflammatory platelet-monocyte interactions. Thromb Haemost 2023; 123 (02) 231-244
• 8 Mumaw MM, de la Fuente M, Noble DN, Nieman MT. Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost 2014; 12 (08) 1331-1341
• 9 French SL, Arthur JF, Lee H. et al. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost 2016; 14 (08) 1642-1654
• 10 Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol 2014; 5: 67